Insulin aspart
FDA approved · RxRapid-acting insulin analog
Also known as: NovoLog, Fiasp, Insulin Diluting Medium For Kirsty, Kirsty, Merilog, Insulin Aspart Protamine And Insulin Aspart Mix 70/30, Novolog Mix 70/30, Insulin-aspart, Aspart, Aspart insulin
Strong, human-grade evidence
- Regulatory standing. FDA-approved prescription medicine
- Human trials. Backed by controlled human studies
- Registered human trials. 614 registered studies on ClinicalTrials.gov, most advanced Phase 4
- 2 cited sources. Includes primary / regulatory sources
Computed with the same four public criteria as every profile. The human-evidence grade on an indexed profile is set automatically and may change when it is hand-reviewed. It is not a safety score, not a purity rating, and not medical advice, and not a claim that this compound treats, cures, or prevents any condition.
What it is
Insulin aspart is a modified form of human insulin in which one amino acid is swapped so the molecules clump together less after injection, letting it be absorbed faster than regular human insulin. Like natural insulin, it helps move glucose from the blood into cells and signals the liver to release less glucose. It is sold under names including NovoLog and Fiasp, and in premixed forms combined with a longer-acting protamine version.
What the evidence shows
Insulin aspart is FDA-approved for improving blood sugar control in adults and children with diabetes mellitus, typically around mealtimes. Its effects are well established through hundreds of registered human trials, including Phase 4 studies, and more than a thousand published papers.
Key facts
Registered human trials
Live from ClinicalTrials.gov, refreshed daily.
Biphasic Insulin Aspart Versus NPH Plus Regular Human Insulin in Type 2 Diabetic Patients
Effect of Biphasic Insulin Compared to Biphasic Insulin Combined With Insulin Aspart, With or Without Metformin in Type 2 Diabetes
Safety and Efficacy of Insulin Degludec/Insulin Aspart in Patients With T2DM
Pilot Study of Clinician-supported Patient Self-management of Hospital Insulin Therapy
Published literature
Live from Europe PMC. This is how much has been published, not how much is proven in humans.
Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use.
Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes.
Three-year efficacy of complex insulin regimens in type 2 diabetes.
Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study.
Sources
- PubChem compound record (CID 16132418)
- FDA drug label on DailyMed
- Registered trials on ClinicalTrials.gov
- Published papers on Europe PMC
Risks, side effects and study doses are only published on hand-reviewed profiles. Want this one reviewed, or spotted something wrong? Tell us.